Canine Idiopathic Inflammatory CNS Disease



Similar documents
Seizures (Convulsions, Status Epilepticus) in Dogs

Seizures and Epilepsy

Neurosarcoidosis. Jeffrey M. Gelfand, MD

SHAKE, RATTLE, AND ROLL: TOP 10 THINGS YOU SHOULD KNOW ABOUT VESTIBULAR DISEASE

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases

Less stress for you and your pet

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis

NEUROLOCALIZATION MADE EASY

A Definition of Multiple Sclerosis

MRI in Differential Diagnosis

Managing Epileptic Dogs By William B. Thomas, DVM,MS, University of Tennessee

FastTest. You ve read the book now test yourself

OHTAC Recommendation

Canine Lymphoma Frequently Asked Questions by Pet Owners

Spinal Cord Diseases in Bernese Mountain Dogs

Immune-Mediated Low Platelet or Thrombocyte Count

Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI

2.1 Who first described NMO?

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare

Original Policy Date

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

Clinical guidance for MRI referral

Cytomegalovirus (HHV5/CMV) Roseolovirus (HHV6 & 7)

A Rare Image. Dean M. Cestari, MD Fred Jakobiec, MD Fred Hochberg, MD Joseph F. Rizzo III, MD Rebecca C. Stacy, MD PhD

AUBAGIO (teriflunomide) oral tablet

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

Congenital Toxoplasmosis Patient Scenario

Chapter 7: The Nervous System

Chapter 10. Summary & Future perspectives

Mary Case, MD Professor of Pathology St. Louis University USA MO Juvenile Justice Association Conference Lake Ozark, MO

Disease Modifying Therapies for MS

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

FUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

C o n s u l t a n t o n C a l l C O N T I N U E D

What Is an Arteriovenous Malformation (AVM)?

Brain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.

Social Security Disability Insurance and young onset dementia: A guide for employers and employees

New Treatment Options for MS Patients: Understanding risks versus benefits

Disease Modifying Therapies for MS

Lymphoma in Dogs: Diagnosis & Treatment

AIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS

1333 Plaza Blvd, Suite E, Central Point, OR *

EVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze

IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)

This 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief.

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010

SARCOIDOSIS AND THE NERVOUS SYSTEM

F r e q u e n t l y A s k e d Q u e s t i o n s

Spontaneous and Surgical Trauma to the Eye. Richard R Dubielzig

Multiple Sclerosis: An imaging review and update on new treatments.

NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso

Cardiovascular diseases. pathology

M2 Pathology Course Phone: Lecture # 72 tiborv@uic.edu Tuesday, February 11, :30 10:20

Canine Immune-Mediated Hemolytic Anemia

Clinical Trials of Disease Modifying Treatments

Chronic Hepatitis/Chronic Active Hepatitis in Dogs

Headache: Differential diagnosis and Evaluation. Raymond Rios PGY-1 Pediatrics

LCD for Viral Hepatitis Serology Tests

Creutzfeldt-Jakob disease and other spongiform encephalopathies

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

Brain Spots on Imaging Tests

Medical Laboratory Technology Program. Student Learning Outcomes & Course Descriptions with Learning Objectives

DIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES

Protein electrophoresis is used to categorize globulins into the following four categories:

Using the ICD-10-CM. The Alphabetic Index helps you determine which section to refer to in the Tabular List. It does not always provide the full code.

Open the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke

Vocabulary & General Concepts of Brain Organization

Paraneoplastic Antibodies in Clinical Practice. Mohammed El lahawi New Cross Hospital Wolverhampton

CNS DEMYLINATING DISORDERS

Developmental delay and Cerebral palsy. Present the differential diagnosis of developmental delay.

ALS and Lyme Disease Questions from Patient and Families Responses from Medical Experts

TUBERCULOSIS PLEURAL EFFUSION - MANAGEMENT

FastTest. You ve read the book now test yourself

Neurology Clerkship Learning Objectives

Biology 141 Anatomy and Physiology I

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!!

CIDP Chronic Inflammatory Demyelinating Polyneuropathy. A publication of the GBS/CIDP Foundation International

The severity of clinical signs depends on the underlying cause of diarrhea, P a t i e n t S u p p o r t P E D I A T R I C S

Multifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD

The neuropathology of CJD

Defining Normal Cerebrospinal Fluid White Blood Cell Counts in Neonates and Young Infants: A Scholarly Pursuit

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

Aggressive vs. nonaggressive bone lesions. Anthony Pease, DVM, MS, DACVR

National MS Society Information Sourcebook

Clinical features. Chapter 2. Clinical manifestations. Course

Systemic Lupus Erythematosus

MS ECHO: Update on MS treatment. Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Inflammation and Healing. Review of Normal Defenses. Review of Normal Capillary Exchange. BIO 375 Pathophysiology

Gateway Health SM Non-Formulary Prior Authorization Criteria Intravenous Immune Globulin (IVIG)

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Transcription:

C o n s u l t a n t o n C a l l N E U R O L O G Y Peer Reviewed Richard A. LeCouteur, BVSc, PhD, Diplomate ACVIM (Neurology) & ECVN University of California Davis Canine Idiopathic Inflammatory CNS Disease PROFILE Definition Inflammatory central nervous system (CNS) diseases are a group of sporadic inflammatory diseases that affect the brain and/or spinal cord in the absence of an infectious cause (ie, pathogen-free). Based on histopathologic findings, 3 distinct forms of inflammatory CNS disease have been identified in dogs: Granulomatous meningoencephalomyelitis (GME): Canine GME is the current term for an idiopathic CNS disease (most likely first described in 1936). GME still attracts a confusing and lengthy number of synonyms reflecting changes only in immunologic terminology (eg, inflammatory reticulosis, lymphoreticulosis, neoplastic reticulosis). Necrotizing meningoencephalitis (NME): Canine NME was originally recognized in dogs in the U.S. in the 1970 s as a breedspecific disease of pug dogs (colloquially known as pug dog encephalitis ). Since 1989, based on morphologically defined lesion patterns and histology, NME has been recognized in other small-breed dogs, including Maltese, Chihuahua, Pekinese, Boston terrier, Shih Tzu, Coton de Tulear, and papillon breeds. Necrotizing encephalitis (NE): Canine NE was first described in 1993 in Yorkshire terriers and has been reported in other breeds, including French bulldogs. Signalment Age GME affects dogs older than 6 months of age, and is most prevalent in dogs between 4 and 8 years of age. Onset of NME is 6 months to 7 years of age, with a mean onset age of 29 months. NE typically manifests between 4 months and 10 years of age, with 4.5 years as a mean onset age. Breed & Sex Predilection GME affects all sizes and breeds of dogs (with toy and terrier breeds overrepresented), whereas NME and NE affect predominantly smallbreed dogs. Both males and females are affected, although females may be at higher risk for developing the disease. Causes Obscure, although an autoimmune or immune-mediated/immune-dysregulatory cause is suspected. PCR-based screening for viral DNA (eg, herpes, adeno- or parvoviruses) has been negative. Pathophysiology Suggested possible mechanisms include autoimmune encephalitis induced by anti-gfap (glial fibrillary acidic protein) antibodies in CSF and T-cell-mediated delayed hypersensitivity mechanisms. C O N T I N U E S CNS = central nervous system; CSF = cerebrospinal fluid; GME = granulomatous meningoencephalomyelitis; NE = necrotizing encephalitis; NME = necrotizing meningoencephalitis; PCR = polymerase chain reaction Consultant on Call / NAVC Clinician s Brief / January 2011...19

C o n s u l t a n t o n C a l l C O N T I N U E D CNS = central nervous system; CSF = cerebrospinal fluid; CT = computed tomography; FLAIR = fluid-attenuated inversion recovery; GME = granulomatous meningoencephalomyelitis; MRI = magnetic resonance imaging; NE = necrotizing encephalitis; NME = necrotizing meningoencephalitis; PCR = polymerase chain reaction Signs Signs of neurologic dysfunction reflect the location of the lesion(s) within the CNS. Multifocal involvement of the cerebrum, brainstem, cerebellum, and spinal cord (GME only) is common. Clinical signs of GME may include visual disturbances (ie, the ophthalmic form of GME affects the optic nerve), cranial nerve deficits (particularly central vestibular signs), seizures, apparent cervical pain, ataxia, and paresis. NME and NE frequently affect the forebrain, resulting in abnormal mentation, seizures, blindness, circling, and behavior changes, or brainstem, resulting in cranial nerve deficits, changes in mentation, and difficulty walking. DIAGNOSIS Definitive Diagnosis A tentative antemortem diagnosis may be based on analysis of a combination of the patient s: Signalment, history, and clinical signs Neurologic examination findings Blood analysis results Infectious disease titers (eg, Toxoplasma, Neospora, fungal organisms, canine distemper) CSF analysis (including culture and PCR analysis) Advanced imaging (CT and MRI) Neurologic signs, CSF analysis results, and neuroimaging findings will vary with intensity and location of pathologic lesions. Definitive antemortem diagnosis is based on characteristic findings on histopathology of brain and/or spinal cord tissue obtained by surgical biopsy. Definitive postmortem diagnosis is based on characteristic findings on histopathology of brain and spinal cord. Differential Diagnosis See Box for other causes of focal and multifocal CNS dysfunction of dogs. Possible Causes of Brain Dysfunction in Dogs Degenerative Lysosomal storage diseases Leukodystrophy/spongy degeneration Cognitive dysfunction syndrome Anomalous/Developmental Congenital hydrocephalus Caudal occipital malformation Intracranial arachnoid cyst Metabolic Hepatic encephalopathy Renal-associated encephalopathy Hypoglycemic encephalopathy Electrolyte-associated encephalopathy Endocrine-related encephalopathies Encephalopathy associated with acidbase disturbances Mitochondrial encephalopathy Neoplastic Primary brain tumors Secondary brain tumors Nutritional Thiamine deficiency Inflammatory/Infectious/Immune-Mediated Bacterial meningoencephalitis Fungal encephalitis Viral meningoencephalitis Protozoal meningoencephalitis Rickettsial meningoencephalitis Verminous meningoencephalitis Granulomatous meningoencephalomyelitis Necrotizing meningoencephalitis Necrotizing encephalitis Eosinophilic meningoencephalitis Toxic Pyrethrins, lead, methylxanthines, zinc phosphate, & metaldehyde Vascular Ischemic encephalopathy Hemorrhagic encephalopathy 20...NAVC Clinician s Brief / January 2011 / Consultant on Call

Laboratory Findings CSF from dogs with inflammatory CNS disease is usually abnormal, although normal CSF may be present (particularly if corticosteroids have been administered up to 6 weeks prior to CSF collection). Typical findings consist of an elevated total nucleated cell count and elevated CSF protein. Lymphocytes are the predominant cell type, with smaller numbers of neutrophils and macrophages present (Figure 1). Infectious causes of CSF abnormalities should be considered, and culture, serologic testing, electrophoresis, or PCR analysis (of CSF and/or serum) for the presence of infectious agents may be appropriate (eg, canine distemper virus), although results of these tests are unlikely to contribute to a diagnosis. Imaging Characteristic findings on MRI include asymmetric, bilateral (often multifocal) lesions in the forebrain, brainstem, and/or spinal cord (Figure 2). These lesions variably enhance with intravenous contrast administration. Cystic areas may be seen in areas of the brain that are necrotic. The classical lesions in GME, NME, and NE may be distinctly different based on both distribution pattern and microscopic lesions. While this information may be helpful in differentiating between the 3 forms of inflammatory CNS disease, it may not be possible to differentiate GME, NME, and NE based on imaging characteristics alone (except that spinal cord involvement is only present with GME). Postmortem Findings A unique histopathologic appearance is present in each of the inflammatory CNS disorders. GME is characterized by a unique angiocentric granulomatous encephalitis consisting of a perivascular accumulation of macrophages often intermixed with lymphocytes and plasma cells. Three major patterns of histologic lesion distribution in the brain and spinal cord have been described for GME: C O N T I N U E S 1 Cytofuge smear of CSF from a 5-year-old spayed female Maltese. Total nucleated cell count was 1057/mcL (reference range, < 3/mcL) with 1% neutrophils, 93% small mononuclear cells, and 6% large mononuclear cells. Protein content was 576 mg/dl (reference range, < 25 mg/dl). These findings are consistent with a diagnosis of GME. (Wright s stain, 100 ) 2 Transverse, FLAIR MRI at the level of the midbrain and cerebral hemispheres of a 4-year-old, castrated male Maltese with acute onset of mild obtundation and generalized ataxia. Note the localized hyperintensity of the white matter throughout the cerebral cortex, with bilateral periventricular edema. Illdefined multifocal hyperintensity is also identified in the brainstem. These findings are consistent with a diagnosis of GME. Consultant on Call / NAVC Clinician s Brief / January 2011...21

C o n s u l t a n t o n C a l l C O N T I N U E D 3 4 5 GME. Disseminated form of GME with an angiocentric expansive infiltration of macrophages sometimes mixed with lymphocytes and a few plasma cells. (H&E stain, 130 ). NME. Intense nonsuppurative meningitis with polioencephalitis and necrotizing leukoencephalitis. The lesions are intensely inflammatory with parenchymal histiocytic, microglial infiltrates accompanied by perivascular cuffing of lymphocytes and plasma cells. (H&E stain, 110 ). NE. Intense histiocytic, microglial, and predominant macrophage cellular infiltrate with extensive destruction and loss of white matter, a characteristic proliferation of reactive astrocytes and thick perivascular lymphocytic cuffing. (H&E stain, 265 ). The disseminated form, in which the most intense lesions occur in the upper cervical spinal cord, brainstem, and midbrain, often with less severe extension involving white matter of the rostral cerebrum (Figure 3). A disseminated form with angiocentric expansion forming multiple coalescing mass lesions of similar distribution. A focal form, in which single discrete mass lesions occur in either the spinal cord, brainstem, midbrain, thalamus, optic nerves, or cerebral hemispheres, without dissemination. It remains contentious whether this form is a neoplastic rather than an immunoproliferative process. NME has both a characteristic anatomic distribution pattern and unique histologic lesions: Gross lesions occur as asymmetrical, multifocal bilateral areas of either acute encephalitis or chronic foci of malacia, necrosis, and collapse of hemispheric gray and white matter decreasing in intensity rostrocaudally. Histologically, there is a unique combination of focal meningitis and polio- and leukoencephalitis of adjacent white matter. The lesions are intensely inflammatory with meningitis and parenchymal histiocytic, microglial infiltrates accompanied by perivascular cuffing of lymphocytes and plasma cells. Coexisting with chronic lesions can be acute nonsuppurative encephalitis in the hippocampus, septal nuclei, and thalamus. Usually, few inflammatory lesions are present in the cerebellum, brainstem, and spinal cord (Figure 4). In canine NE, the large focal asymmetric bilateral malacic necrotizing lesions are confined mostly to the white matter of the cerebral hemispheres. There is an intense histiocytic, microglial, and macrophage cellular infiltrate with loss of white matter and thick perivascular lymphocytic cuffing. Other areas have acute exudation, severe edema, necrosis, and eventual cyst formation, with a dramatic gemistocytic astrogliosis, histiocytes, and gitter cells intermixed with thick perivascular lymphocytic cuffing. Characteristically, the overlying cortex and meninges are not involved. Multifocal intense inflammatory cell infiltrates of macrophages with dramatically thick perivascular lymphocytic cuffing are seen in the midbrain, brainstem, and cerebellum (Figure 5). TREATMENT Medical Therapy is based on the use of immunomodulatory drugs at immunosuppressive doses. The most common therapy utilized is corticosteroids. Dogs often have a favorable response to corticosteroid monotherapy, but response may be temporary. Other immunomodulatory drugs may be used if the dog does not tolerate corticosteroids, to reduce the dose of corticosteroids, or if there is inadequate clinical response to corticosteroids. Many drugs have been recommended, including: Cyclosporine Procarbazine Lomustine (CCNU) Leflunomide Mycophenolate mofetil (MMF) Azathioprine 22...NAVC Clinician s Brief / January 2011 / Consultant on Call

Cytosine arabinoside All have been used by different authors in relatively small numbers of patients. There is no published evidence of the risks and/or benefits of these treatments when compared to the use of immunosuppressive regimens of corticosteroids alone. The author recommends starting treatment with immunosuppressive doses of prednisone, giving the patient: 1.5 mg/kg Q 12 H for 3 weeks 1 mg/kg Q 12 H for 6 weeks 0.5 mg/kg Q 12 H for 3 weeks 0.5 mg/kg Q 24 H for 3 weeks 0.5 mg/kg every other day indefinitely After the first 4 to 6 weeks of prednisone therapy, cytosine arabinoside may be added at 3 to 6 week intervals (administered as a subcutaneous injection, 50 mg/m 2 Q 12 H for 2 consecutive days). Precautions Adverse effects of long-term high-dose corticosteroid therapy include polyuria/polydipsia, polyphagia, weight gain, hepatotoxicity, gastrointestinal ulceration, pancreatitis, and iatrogenic hyperadrenocorticism. Adverse effects of cytosine arabinoside are dose dependent, including myelosuppression, vomiting, diarrhea, and hair loss. Activity No exercise restrictions are recommended. Client Education Clients should be informed that there is no definitive treatment for inflammatory CNS diseases of dogs. Therapy is aimed at suppressing the dog s immune system for as long as possible. FOLLOW-UP Patient Monitoring Regular rechecks (suggested at monthly intervals or as needed) should be performed to assess progress of disease and adverse effects of medications. Repeat CBCs, serum biochemical profiles, urinalysis, CSF analysis, and advanced imaging may be necessary. IN GENERAL Relative cost Diagnosis and long-term management are costly due to the need for specialized diagnostic procedures, immunomodulatory drug maintenance, and repeated assessments ($$$$$). Prognosis Prognosis for dogs with inflammatory CNS disease is poor, and most affected dogs eventually die or are euthanized. Some survive only a short period of time, while others have a more prolonged clinical course from 6 months to, rarely, years. Future Considerations Research to date on canine inflammatory CNS diseases and the nature of the histopathologic lesions suggest the likelihood of an autoimmune or immune-mediated/ immunedysregulatory disease. In humans, many autoimmune diseases have strong associations with certain MHC genotypes and this information may be used to assist in diagnosis or patient counseling. It is now possible to determine the MHC haplotype of dogs, and some disease associations with MHC haplotype in dogs have already been demonstrated. Assessment of MHC haplotype in dogs with GME may help determine if there is a genetic component to disease susceptibility and development. Cost Key $ = < $100 $$ = $100 $250 $$$ = $250 $500 $$$$ = $500 $1000 $$$$$ = > $1000 See Aids & Resources, back page, for references & suggested reading. CBC = complete blood count; CNS = central nervous system; CSF = cerebrospinal fluid; GME = granulomatous meningoencephalomyelitis; MHC = major histocompatibility complex; NE = necrotizing encephalitis; NME = necrotizing meningoencephalitis Consultant on Call / NAVC Clinician s Brief / January 2011...23